BioMedPartners advises the divesting funds BioMedInvest I, BioMedInvest II and BioMedInvest III.
BioMedInvest III L.P. is a healthcare-dedicated venture capital fund that had a first closing of CHF 75 million in February 2017, with the final closing in February 2018 at CHF 100 million. It is based and managed in Guernsey, Channel Islands, and provides venture capital financing to early-stage private companies and spin-offs in the biotechnology, emerging pharmaceutical, medical technology and other healthcare-related industries such as diagnostics or platform technologies with a geographic focus on investments in Switzerland, Germany and neighboring countries of the European Union.
The fund is closed for new investments.
ALENTIS Therapeutics, based in Basel (CH) and Strasbourg (F), is a spin-out of the University of Strasbourg developing novel therapeutics for advanced liver disease and cancer.
Allecra therapeutics is based in the European BioValley Life Sciences cluster located in the Upper Rhine valley (D, F and CH) and is focused on the development of novel treatments to combat multi drug-resistant Gram-negative bacterial infections.
AMAL Therapeutics, based in Geneva (CH), is focused on cancer immunotherapy. The company’s proprietary technology platform, “KISIMA®”, leverages a first-in-class peptide/protein-based vaccination technology. AMAL’s lead vaccine ATP128 is currently developed for stage IV colorectal cancer. In July 2019, Boehringer Ingelheim acquired AMAL Therapeutics for up to EUR 325 Mio., plus up to EUR 100 Mio. if certain commercial milestones are hit.
Azafaros is a Basel-based company addressing rare lysosomal storage diseases through a pipeline of oral small molecules with disease-modifying potential.
Cardior Pharmaceuticals is a spin-off from the Hannover Medical School (D) focusing on developing non-coding RNA based therapeutics and diagnostics for the treatment of heart failure.
ImmunOs Therapeutics, a spin-off of the University of Zurich and University of Basel (CH), is leading the discovery and development of the next generation of novel human immunomodulatory proteins involving the innate immune system for cancer treatments that not only have direct anti-tumor effects but also remodel the tumor microenvironment and enhance the efficacy of existing immunotherapies.
Noema Pharma is a Swiss-based company targeting orphan neurological disorders characterized by imbalanced neuronal networks. The company is developing four mid-clinical-stage therapeutic products in-licensed from Roche and with strong safety packages. Lead product NOE-101, an mGluR5 inhibitor, is Phase 2b-ready for two indications: persistent seizures in Tuberous Sclerosis Complex (TSC) and severe pain in Trigeminal Neuralgia (TN). NOE-105, a PDE10A inhibitor, is in preparation for Phase 2b testing to treat Tourette Syndrome. The Company is undertaking validation studies in undisclosed indications for two additional clinical-stage assets, NOE-109, an mGluR2/3 inhibitor, and NOE-115, a triple re-uptake inhibitor.
PRECIRIX is a spin-off from VUB (Vrije Universiteit Brussel, Belgium), developing new radiopharmaceuticals based on linking single domain antibody fragments with radioisotopes to treat cancer.
Scenic Biotech B.V. is a spin-out of the Netherlands Cancer Institute and Oxford University, applying its Cell-Seq platform technology to progress a pipeline of genetic modifiers in cancer and rare diseases.
TOLREMO Therapeutics AG is a spin-off from ETH Zurich (CH) targeting novel mechanisms to prevent resistance development to cancer therapies.
Topas Therapeutics GmbH is a privately held German biotech company with lab facilities in Hamburg, Germany. Topas Therapeutics is currently performing a Phase I studies in Pemphigus Vulgaris (PV) patients, an autoimmune disease attacking the human skin. Topas pursues a unique approach in tolerization of the immune system against known antigens using a patented therapeutic concept for peptide‐nanoparticle‐formulation. The fundamental biology of Topas approach is that the liver provides a tolerogenic environment and presented antigens (including auto‐antigens, delivered to appropriate sinusoidal cells in the liver) will elicit a tolerogenic response as opposed to an immunogenic response.
Tricares SA, based in Munich (D) and Paris (F), is a medical device company devoted to developing a catheter-based valve replacement system for minimal invasive treatment of tricuspid valve regurgitation.
Tubulis GmbH is a Munich based company generating uniquely matched protein-drug conjugates by combining proprietary novel technologies with disease specific biology. The company is developing novel antibody drug conjugates (ADCs) which deliver better outcome for patients.
BioMedInvest II L.P. is a healthcare-dedicated venture capital fund that was closed in 2009 and has a size of CHF 106 million. It is based and managed in Guernsey, Channel Islands, and provides venture capital financing to early-stage private companies and spin-offs in the biotechnology, emerging pharmaceutical, medical technology and other healthcare-related industries such as diagnostics or platform technologies with a geographic focus on investments in Switzerland and neighboring countries.
The fund is closed for new investments.
Activaero GmbH, a spin-off from the German National Research Center GSF is the worldwide technology leader for controlled inhalation of aerosols. In March 2014, Activaero was acquired by the British Vectura Group plc.
Aleva Neurotherapeutics SA with its headquarter at the EPFL Campus in Lausanne develops next-generation implants for Deep Brain Stimulation (DBS) in major neurological indications such as Parkinson's disease or depression.
Anergis SA, based in Epalinges (CH), develops and markets peptide-based immunotherapies for the treatment of common allergies.
Ayoxxa Biosystems GmbH, based in Köln (D), is a spin-off from the National University of Singapore which develops a proprietary technology platform for multiplexed protein analysis. This technology enables multiplex analysis in very small volumes with a very high robustness.
Curetis AG, located in Holzgerlingen (D), is a molecular diagnostic company focusing on the development and commercialization of reliable, fast and cost-effective tools for diagnosing severe infectious diseases.
Evolva Holding SA is a Swiss-listed (SIX: EVE), international biotech company with its headquarters in Reinach, near Basel. Its mission is to discover and provide innovative, sustainable ingredients for health, nutrition and wellness. Evolva uses biosynthetic and evolutionary technologies to create and optimise small molecule compounds and their production routes.
Genkyotex S.A., based in St. Julien-en-Genevois (F) and Geneva (CH), is the leading developer of targeted NADPH Oxidase (NOX) inhibitors, with its lead compound in Ph II diabetic nephropathy.
Hookipa Biotech AG, based in Vienna (A), is a clinical stage company developing next-generation immunotherapies for infectious diseases and cancer using novel proprietary arenavirus vector platforms. Hookipa´s TheraT® and Vaxwave® platforms have shown promising abilities to elicit high neutralizing antibody responses, but also necessary levels of T cell responses, currently missing in most vaccine and therapeutic approaches.
Humedics GmbH, headquartered in Berlin (D) and founded in 2010, has an innovative breath analysis device that makes instant bedside measurement of liver functions of patients with critical liver failure.
ImevaX GmbH is a spin-off from Technische Universität München which develops highly specific vaccines against pathogens which cause chronic infectious diseases.
Inotrem S.A. is a French biotech company specializing in the discovery and development of novel treatments in the field of inflammatory pathologies with a special focus on critical care.
Middle Peak Medical, based in Munich (D), is a medical device company, focusing on the development of a break-through device to meet unmet needs in the treatment of mitral valve disease. In February 2017, Middle Peak Medical was acquired by Symetis SA, a BioMedInvest AG I Portfolio company.
Miracor Medical Systems GmbH is an Austrian medical device company dedicated to improve clinical outcome of patients with impaired cardiac function. Their PICSO Impulse System consists of a console and catheters and is CE marked. In clinical trials, PICSO has successfully demonstrated a reduction in infarct size in acute heart attack patients.
Sequana Medical AG is a Swiss medical device company, headquartered in Zug, dedicated to improving patient lives through the development, manufacture and commercialization of innovative implantable pump systems to manage fluid balance within the body.
VAXIMM AG is a spin-out vaccine company from MerckSerono and primarily focuses on developing active immunotherapies (vaccines) for patients suffering from cancer. The initial product candidate VXM01 is targeting the tumour vasculature, which is essential for tumours to grow beyond microscopic size.
Ventaleon GmbH, based in Gauting (D), is a spin-off of Activaero GmbH which develops inhaled Lysine Acetylsalicylate Glycine programme for the treatment of severe hospitalized influenza.
BioMedInvest AG I in liquidation was a healthcare-dedicated investment company, providing private equity financing to early- to mid-stage companies in the biotechnology, emerging pharmaceutical, medical technology and other healthcare-related industries in Switzerland and neighbouring regions (Alpine Rim). BioMedInvest I was closed in 2003 and had a size of CHF 100 million. In 2011, BioMedInvest AG I merged with BioMedCredit AG.
The fund is in liquidation.
4-Antibody, a wholly-owned subsidiaryof Agenus Inc., is located in Basel, Switzerland and Jena, Germany. Agenus is a Nasdaq-listed company with a partnered late-stage adjuvant pipeline, vaccine candidates in clinical phase II, and checkpoint antibodies in preclinical testing derived from 4-Antibody. These antibody therapeutics focus on immuno-oncology targeting checkpoint modulators such as GITR, OX40, CTLA-4, PD-1, TIM-3, and LAG-3.
7TM Pharma was a Danish discovery and development company which focused on new medicines targeting 7TM receptors, and had anti-obesity compounds in early stage of clinical development.
Affimed Therapeutics AG, based in Heidelberg (D), is a biopharmaceutical company focusing on the development of next generation antibodies against various indications using its proprietary antibody format technology platform. The company went public on the Nasdaq (symbol: AFMD) in September 2014
Arpida was a publicly quoted biopharmaceutical company that focused on the discovery and development of novel products for the treatment of bacterial infections. In December 2009, the company merged with Evolva Holding AG.
Delenex Therapeutics was a Zurich-based clinical-stage biotechnology company focusing on research and development of antibody fragments for delivering next generation therapeutic application. The company was created as a spin-off of ESBAtech in 2009 and was acquired in July 2016 by the British company Cell Medica Ltd.
Dolthera was a development-stage biopharmaceutical company discovering and developing a novel class of nucleic acid based anti-inflammatory drugs which were based on oligonucleotides that act as decoys for disease-related transcription factors.
ESBATech AG is a biopharmaceutical company focusing on the development of fully human single-chain antibody fragments for new therapeutic applications with high stability, affinity and production yields. It was acquired by Alcon Research Ltd. in September 2009.
Eyesense is a spin-out from Ciba Vision AG, located in Grossostheim (D), which develops ophthalmic diagnostic systems focusing on glucose testing for diabetic patients. They make blood glucose control easier and pain-free through innovative monitoring devices.
GlycArt Biotechnlogy was a biopharmaceutical company developing a new generation of antibodies based on its proprietary GlycoMAb technology. The company was acquired in 2005 Roche for CHF 235 million. In July 2014, its lead product Gazyvaro was approved against CLL in Europe.
Okairòs AG was a spin-off company from the IRBM in Rome (Merck Inc.) focusing on the discovery and development of genetic T-cell vaccines including hepatitis C virus (HCV). In May 2013, Okairos AG was acquired by GlaxoSmithKline for EUR 250 million.
Oncalis AG was a biotech company that focused on the discovery and development of small molecule kinase inhibitors for oncology indications using its proprietary yeast-cell based, high-throughput screening platform for receptor tyrosine kinases. The company was liquidated end of 2012.
Polyphor AG, headquartered in Allschwil (CH), is a biotech company developing focused small molecule libraries for lead optimization and novel compound classes Protein Epitope Mimetics (PEM) which combine elements of protein and classical small molecules. The company went public on SIX Swiss Exchange (symbol: POLN) in May 2018.
Santhera Pharmaceuticals is a publicly quoted biotech company that focuses on the development of small molecule drugs for treating neuromuscular and neurodegenerative diseases.
Spinelab AG is a medical technology company focusing on dynamic spine stabilization devices with the aim to preserve some level of motion, facilitate load/stress sharing, provide stability and maintain sagittal alignment.
SuppreMol GmbH was a privately held biopharmaceutical company based in Munich (D), developing and manufacturing novel immunomodulatory molecules for the treatment of autoimmune diseases. In March 2015, SuppreMol GmbH was acquired by Baxter International for USD 225 million.
Symetis SA was a leader in minimally-invasive transcatheter heart valve implantation devices to treat valvular heart disease. The company has safe and intuitive aortic heart valve replacement systems that alleviate the burden of disease of high-risk patients suffering from severe aortic stenosis. Their devices give physicians greater control during delicate surgical interventions and result in superb patient outcomes. In May 2017, Symetis SA was acquire by Boston Scientific for USD 435 million.
Thommen Medical is an oral implant company dedicated to develop, manufacture and market a new dental implant system. In 2007, Thommen Medical announced that two groups of private investors have acquired the majority of the company from venture capital investors.
BioMedCredit was a healthcare- and life science-dedicated mezzanine fund providing growth and expansion capital in form of repayable, interest-bearing loans to small- and mid-size private companies in Switzerland. BioMedCredit merged with BioMedInvest I in 2011.
Biognosys, a spin-off from ETH Zurich, is a pioneer in the field of proteomics and caters to the Pharma, Biotech, Diagnostics and Personal Healthcare industries.
BC Platforms is a pioneer in bioinformatics and genome data management.
Their software platform provides answers to today's most groundbreaking research
questions in next-generation sequencing (NGS) and genome-wide association studies
(GWAS).
DS was a technology platform company (ETH spin-off) developing novel degradable implants. End of 2011, the company was acquired by the Japanese Sunstar group.
Develco Pharma AG is a galenic drug development company developing novel generic formulations and application forms for pharmaceutical products.
GeneBio SA, located in Geneva, is a leading bioinformatics company providing the life sciences community with world-class software.
idiag AG is a medical technology company based in Fehraltorf (ZH) which develops and sells innovative products for diagnostic, therapy and sports applications.
Imetric 3D SA is a medical device company which develops dental scanners for the laboratory equipment. The company is based in Courgenay in the Canton Jura.
KLIMAmed developed and produced patient warming systems. The company was located in Kreuzlingen and became insolvent in 2009.
Lipomed AG is a Swiss pharmaceutical company specialized in the research, development and manufacturing of pharmaceuticals and products for the treatment of rare diseases.
Occlutech GmbH, a medtech company headquartered in Schaffhausen (CH), has developed into one of the world's leading companies in structural heart disease over the past decade, developing and supplying various occluders and accessories in more than 80 countries worldwide.
Sias, based in Hombrechtikon (CH), is a leading developer and supplier of innovative multi-tipped robotic XYZ liquid handling systems and robot-friendly functional modules for Laboratory Automation. BioMedInvest AG I's investment in Sias AG results from BioMedCredit AG's initial investment in Xiril AG.
Sonetik AG (Switzerland) is an ISO - certified Swiss manufacturer of audiometers, hearing aids and related accessories whose preprogrammed hearing aids are offered for a trial and for purchase at places to which hearing impaired people have always turned to with health questions.
Spineart is a privately held medical device company focused on simplifying the surgical act by designing, developing and promoting safe and efficient solutions to spine surgeons, operating room teams, and patients.
TRI Dental Implants Int. AG is a Swiss emerging leader in innovative modern implant dentistry, headquartered in Hünenberg (CH). Its name "TRI" is the abbrevation of "Through Research Innovative".
